May 15, 2025
LA JOLLA—Horacio Valeiras, CEO of Frontier Global Partners, has been newly appointed to the Salk Institute’s Kuratorium. He will work alongside business and nonprofit leaders from around the world, all committed to supporting Salk’s innovative, high-quality scientific research.
Valeiras started as a chemical engineer, which laid a scientific foundation that informed his MBA studies and 40-year career in finance. Originally from Buenos Aires, Argentina, Valeiras traveled from New York to London for work before settling in La Jolla more than 20 years ago.
“Horacio’s keen understanding of global technology markets makes him a tremendous asset to all of us at Salk,” says Salk President Gerald Joyce. “He truly understands our mission, priorities, and needs, and we look forward to benefitting from his expertise in the coming years.”
Valeiras earned his bachelor’s degree in chemical engineering at Virginia Tech and his master’s degree at MIT. While in Boston, he began taking business classes and quickly realized the discipline and analytical skills he developed as an engineer were also powerful business skills. This inspired his postgraduation pivot from chemicals research at Chevron to earning his MBA at UC Berkeley, which allowed him to take on investment roles at Anderson & Sherrerd and later act as managing director of Morgan Stanley Investment Management. Valeiras went on to serve as chief investment officer at Allianz Global Investors in 2002, and he later founded HAV Capital LLC, which merged into Frontier Global Partners, where he’s currently CEO.
“Science has always been the foundation of my practice, so joining the Board of Trustees at a prestigious basic research institute like Salk is truly meaningful to me,” says Valeiras. “Supporting the work of Salk’s world-renowned scientists will be an enriching and exciting endeavor in the years to come.”
Büro für Kommunikation
Telefon: (858) 453-4100
press@salk.edu
Das Salk Institute ist ein unabhängiges, gemeinnütziges Forschungsinstitut, das 1960 von Jonas Salk, dem Entwickler des ersten sicheren und wirksamen Polio-Impfstoffs, gegründet wurde. Die Aufgabe des Instituts besteht darin, grundlegende, kooperative und risikofreudige Forschung voranzutreiben, die sich mit den dringendsten Herausforderungen der Gesellschaft befasst, darunter Krebs, Alzheimer und die Gefährdung der Landwirtschaft. Diese Grundlagenforschung bildet die Basis für alle translationalen Bemühungen und führt zu Erkenntnissen, die neue Medikamente und Innovationen weltweit ermöglichen.
